Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAG | P20916 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17283437 | 0.90 | MAPK1 (0.42) | LMNASMN1; SMN2L3MBTL1LGALS8HTT | |
| SCHEMBL24239909 | 0.90 | LMNA (0.47) | LMNASMN1; SMN2L3MBTL1MAPTKMT2A | |
| SCHEMBL24294567 | 0.89 | LMNA (0.43) | LMNASMN1; SMN2L3MBTL1MAPTKMT2A | |
| SCHEMBL23777371 | 0.86 | LMNA (0.40) | LMNASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL24239904 | 0.85 | LMNA (0.52) | LMNASMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL23777341 | 0.84 | MAPK1 (0.41) | KMT2AMEN1LGALS8MAPK1LGALS3 | |
| SCHEMBL18875836 | 0.83 | TGM2 (0.40) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL18875834 | 0.83 | TGM2 (0.40) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL18875837 | 0.82 | TGM2 (0.39) | LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL30980624 | 0.82 | MAPK1 (0.52) | LMNASMN1; SMN2KMT2AMEN1LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ERBB2, PCNA, MRE11 | LMNA 1950/4885SMN1; SMN2 1422/4885L3MBTL1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.